SIM
HZNP

Strategic Investment Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Strategic Investment Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-16,416
Closed -$272K – 138
2016
Q1 		$272K Buy
16,416
+5,807
+55% +$102K 0.14% 58
2015
Q4 		$229K Buy
+10,609
New +$207K 0.13% 74

Other funds holding HZNP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Strategic Investment Management's HZNP Position: Q2 2016 in Review

Strategic Investment Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2016, closing a stake of 16,416 shares — an estimated $272K sold.

Strategic Investment Management first reported a position in HZNP in Q4 2015 and held it in 2 quarters. The position peaked at $272K in Q1 2016. 198 funds tracked by Wall St. Rank hold HZNP as of Q2 2016.

  • Strategic Investment Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2016 after selling out during the quarter.
  • Strategic Investment Management sold 16,416 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2016, an estimated $272K.
  • Strategic Investment Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2015 and held it in 2 quarters.
  • Strategic Investment Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $272K in Q1 2016.
  • 198 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2016.

Based on Strategic Investment Management's 13F filing for Q2 2016, filed 15 Aug 2016.